Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:1053:207-220.
doi: 10.1007/978-3-319-72077-7_10.

Engineering Antibodies for the Treatment of Infectious Diseases

Gaowei Fan  1 , Jinming Li  2
Affiliations
Review

Engineering Antibodies for the Treatment of Infectious Diseases

Gaowei Fan et al. Adv Exp Med Biol. 2017.

Abstract

Historically, serum therapy was previously used to combat infectious pathogens. However, serum sickness and anaphylaxis limited its broad application. The advancement of antibody engineering technologies has made it feasible to generate monoclonal antibodies. There are divergent methods for antibody engineering and optimization. In this chapter, we summarized the latest developments in engineering antibodies for infectious diseases.

Keywords: Engineering antibodies; Pathogens; Treatment.

PubMed Disclaimer

Figures

Fig. 10.1
Fig. 10.1
Chimeric antibodies and humanized antibodies The orange segments originates from murine, the green segments are from human.
Fig. 10.2
Fig. 10.2
Formats of bispecific antibodies
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abboud N, Chow S-K, Saylor C, Janda A, Ravetch JV, Scharff MD, Casadevall A. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med. 2010;207:2395–2405. doi: 10.1084/jem.20100995. - DOI - PMC - PubMed
    1. Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce BG, et al. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One. 2014;9:e100325. doi: 10.1371/journal.pone.0100325. - DOI - PMC - PubMed
    1. Baca M, Presta LG, O’Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem. 1997;272:10678–10684. doi: 10.1074/jbc.272.16.10678. - DOI - PubMed
    1. Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BAC, Nurmohamed MT. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis. 2006;65:1249–1250. doi: 10.1136/ard.2005.049858. - DOI - PMC - PubMed
    1. Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, Li H, Holland PC, Johnson S, et al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother. 2010;54:2431–2436. doi: 10.1128/AAC.01178-09. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources